



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

m

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/611,533	06/30/2003	Scott A. Waldman	08321-0169 CT1	4518
35148	7590	01/22/2007		EXAMINER
COZEN O'CONNOR, P.C..				YU, MISOOK
1900 MARKET STREET				
PHILADELPHIA, PA 19103-3508				
			ART UNIT	PAPER NUMBER
				1642

SHORTENED STATUTORY PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE
3 MONTHS	01/22/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

Office Action Summary	Application No.	Applicant(s)	
	10/611,533	WALDMAN ET AL.	
	Examiner	Art Unit	
	MISOOK YU, Ph.D.	1642	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 22 November 2006.
 2a) This action is FINAL. 2b) This action is non-final.
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-20,25-32 and 34-39 is/are pending in the application.
 4a) Of the above claim(s) 4-7, 14-17, 25-28, 32-38 is/are withdrawn from consideration. My 1-16-07
 5) Claim(s) _____ is/are allowed. 32, 34-38
 6) Claim(s) 1-3,8-13,18-20,29-31 and 39 is/are rejected.
 7) Claim(s) _____ is/are objected to.
 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) Notice of References Cited (PTO-892)
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
 3) Information Disclosure Statement(s) (PTO/SB/08)
 Paper No(s)/Mail Date _____.

- 4) Interview Summary (PTO-413)
 Paper No(s)/Mail Date. _____.
 5) Notice of Informal Patent Application
 6) Other: Exhibit A and B

My 1-16-07

DETAILED ACTION

Election/Restrictions

Applicant's election with traverse of group I in the reply filed on 11/22/2006 is acknowledged. The traversal is on the ground(s) that group I and II are related such that searching together would not impose a serious burden on the examiner. This is not found persuasive because group I requires search of nucleic acid for the claimed detection method while group II requires search of antibody. The search for nucleic acid and antibody do not overlap, thus requiring a serious burden on the examiner.

The requirement is still deemed proper and is therefore made FINAL.

Claims 4, 14, 24, 28, 32, are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim.

Claims 5-7, 15-18, 25-28, 32, 34-38 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim.

Claims 1-20, 25-32, and 34-39 are pending. Claims 1-3, 8-13, 18-20, 29-31, and 39 are examined on merits.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-3, 8-13, 18-20, 29-31, and 39 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

This written description is made because the scope of the limitation "CDX1" is interpreted according to the specification. The specification has following definition for the claimed CDX1:

[0013] As used herein, the term "CDX1" is meant to refer to the cellular protein expressed by normal colorectal cells, as well as primary and metastasized colorectal, stomach and esophageal cancer cells. In normal individuals, CDX1 is found exclusively in cells of intestine, in particular in cells in the duodenum, small intestine (jejunum and ileum), the large intestine, colon (cecum, ascending colon, transverse colon, descending colon and sigmoid colon) and rectum.

[0051] The amino acid of the CDX1 protein and the nucleotide sequence of the CDX1 gene transcript is set forth in GenBank Accession No. XM 003791, which is incorporated herein by reference.


Search of GenBank Accession No. XM 003791 in the NCBI web site in both the protein and nucleic acid databases results in "No items found". Note the attached exhibits A and B. The definition of CDX at Paragraph [0013] is interpreted as a single gene product deposited as GenBank Accession No. XM 003791, not any gene product with the same expression, for example, guanylin cyclase. Note paragraph 15 of US 6767704.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MISOOK YU, Ph.D. whose telephone number is 571-

272-0839. The examiner can normally be reached on 8 A.M. to 5:30 P.M., every other Friday off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Shanon Foley can be reached on 571-272-0898. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.



MISOOK YU, Ph.D.
Primary Examiner
Art Unit 1642

Exhibit A^m

NCBI

All Databases PubMed Nucleotide Protein Genome Structure PMC Taxonomy Books

Search **Nucleotide** for XM 003791

Limits Preview/Index History Clipboard Details

See Details. No items found.

About Entrez

Show only records from: CoreNucleotide (0), EST (0), GSS (0). [\[What's this?\]](#)

Entrez Nucleotide

[Help](#) | [FAQ](#)

Entrez Tools

Check sequence
revision history

LinkOut

My NCBI (Cubby)

Related resources
BLAST

Reference sequence
project

Search for Genes

Submit to GenBank

Search for full length
cDNAs

[Disclaimer](#) | [Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)

Dec 18 2006 06:34:27

Exhibit B

About Entrez

Entrez Protein

[Help](#) | [FAQ](#)

Entrez Tools

[Check sequence
revision history](#)

LinkOut

My NCBI

Related resources
[BLAST](#)

Reference sequence
project

Search for Genes

[Clusters of orthologous
groups](#)

[Protein reviews on the
web](#)

Search for full length
cDNAs

[Disclaimer](#) | [Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)

Dec 18 2006 06:34:27